Sevoflurane, Isoflurane and Desflurane Market to Reach USD 1.5 billion by 2022

The Sevoflurane, Isoflurane and Desflurane Market is expected to reach USD 1.5 billion by 2022 in comparison to USD 1.2 billion in 2014. These three chemicals are inhalation agents and have been used by anesthesiologists, nurse anesthetists, and anesthesiology assistants on a consistent basis. They are very strong and cost less, with minimum damage to the ozone layer.  

Market Drivers

One of the primary factors, triggering expansion in the sevoflurane, isoflurane and desflurane market includes cardiovascular and respiratory diseases affecting the geriatric population. Rising cancer, orthopedic, spinal and gastro-intestinal cases have also furthered the market. Cataract surgery is a major contributor to the global market and will need a higher production of these chemicals.

Growing accidents and emergency cases also add income to the inhalation anesthesia market. Universal insurance coverage as well as constant improvements in medical infrastructure also ensure the development of the sevoflurane, isoflurane and desflurane market. These agents are administered to patients prior surgery, making the induction of general anesthesia much simpler.

A major factor hindering the market is the quantity of CO₂ released in the environment,   leading to global warming. Actually, only about 5 percent of the gases are consumed by patients. The rest are released into the atmosphere and make it unhealthy. The most practical solution for this problem is the anesthetic recycling of products used during the administration of general anesthesia.

Browse Details of  Report@ https://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry

Products Overview

Sevoflurane

Sevoflurane is one of the most commonly used volatile anesthetic agents. It is administered to babies and children. Sevoflurane is ideal for patients with asthma or sensitive air passages. But its side-effects include delirium and agitation. It can be given quickly without the use of intravenous instruments.

Sevoflurane would capture over 70% of the worldwide sevoflurane, isoflurane and desflurane market by 2022. The agent is expected to exceed USD 1 billion by the same year. It’s widely utilized for being low-priced and possessing therapeutic benefits.

Isoflurane

Isoflurane is a halogen ether utilized frequently by veterinarians. It is administered intravenously, relaxes the muscles and reduces pain. Isoflurane has also been used for inducing sleepiness for long durations during surgery. It is expected to register a CAGR of about 10% by 2022.

Desflurane

Desflurane is a halogen ether used in general anesthesia. Its effectiveness is one-fifth of isoflurane. Desflurane cannot be administered orally and requires an electrically heated dispenser to distribute the vapor. It is mostly administered to bariatric patients and in cases of surgeries lasting for short durations.

Regional Overview

The United States has a large geriatric population. This has led the region of North America to occupy the biggest share in the worldwide inhalation anesthesia market in 2014. Surgical ambulatory and inpatient procedures are the driving factors of North America.

Asia Pacific will experience the fastest growth by 2022. This is owing to the rise of chronic diseases and need for better health infrastructure in the region. Medical tourism combined with insurance coverage will play a huge role in sustaining the growth of the sevoflurane, isoflurane and desflurane market.

Key Players

The market is currently dominated by AbbVie and Baxter International. However, it can   expect strong competition from manufacturers like Lunan Pharmaceutical Group and Piramal Enterprises.

Piramal Enterprises currently has isoflurane and sevoflurane production underway. It will manufacture generic desflurane by 2016. AbbVie has sevoflurane and isoflurane under production. Baxter International is the only one that manufactures all the three products.

Anesthesia has some unhealthy effects. The recycling companies of Deltasorb Technologies and Anesthetic Gas Reclamation reprocess anesthesia containers and gases from hospital vents. Rising investments by the aforementioned players would also accelerate the sales of the sevoflurane, isoflurane and desflurane market.

Related Reports @

Doxorubicin Market: Doxorubicin market is expected to witness a significant growth in the developed regions due to the multiple incidences of cancer occurrence in these regions. 

Antidiabetic Drug Market : The global antidiabetic drug market is expected to witness substantial growth over the forecast period on account of increasing occurrence 

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - https://www.hexaresearch.com

Molecular Diagnostics Market Size and Technology

The Molecular Diagnostics Market was valued at over USD 6.40 billion in 2015. It is likely to grow at a CAGR of around 9% during the forecast period (2016-2024).

Increasing prevalence of infectious diseases, cancer, genetic disorders, and other contagious disease are likely to drive the molecular diagnostics industry. Hospital acquired infections and other communicable infections are expected to boost market growth in the coming eight years. Moreover prenatal genetic testing is also expected to increase the adoption of this diagnostics.

Unhealthy lifestyle can further contribute to large number of people getting afflicted with chronic ailments like cardiovascular disorders and diabetes. This with further propel market growth in the coming years. Molecular diagnostics market is divided into products, technologies, applications, test location, and regions.

On the basis of products, the market is split into instruments, reagents, and others. Reagents segment held the largest share in 2015 with revenues exceeding USD 3.5 billion. It is expected to grow at a CAGR surpasing 12%. Instruments segment is expected to show a significant growth in the coming years.

Browse Details of Report @ https://www.hexaresearch.com/research-report/molecular-diagnostics-industry

Technologies consist of polymerase chain reaction (PCR), in-situ hybridization, chips and microarrays, mass spectrometery, DNA sequencing, transportation mediated amplification, and others. PCR held the largest market share of over USD 2.5 billion in 2015. Growth of this segment can be attributed to its high incorporation among the researchers and healthcare professionals. DNA sequencing is likely to show a growth of about 16% CAGR in the coming years.

Applications encompass oncology, pharmacogenomics, infectious diseases, genetic testing, neurological diseases, cardiovascular diseases, and others. Infectious diseases segment was the largest application holding market share exceeding 45% in 2015.

Oncology segment is anticipated to show a CAGR of about 13% till 2024. Rising awareness among people regarding early cancer diagnosis is the key aspect propelling market growth of the segment.

Test location comprises of point of care (PoC), self test or over the counter (OTC), and central laboratories. Central laboratories dominated the market with over 60% shares in 2015. The growth of the central laboratories can be attributed to their large prominence in underdeveloped countries, rising awareness about early detection of diseases, and high procedure volumes.

The PoC is expected to project a lucrative growth with a CAGR of more than 14%. The growth of this segment can be attributed to the increasing demand of bedside patient monitoring and innovative technological devices.

Regions are fragmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa (MEA). America dominated the market with over 40% revenue share. Asia Pacific is likely to exhibit a growth of around 12%CAGR in the coming years.

The key global players of the molecular diagnostics market include Siemens Healthcare GmbH, Novartis AG (Grifols), F. Hoffmann-La Roche Limited, and Johnson & Johnson.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/biotechnology-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Global Guidewires Market To Witness Rapid Growth From 2016 To 2024

Guidewires are flexible tubes used to guide a catheter to a diseased artery in the heart. They are used for the diagnosis of cardiovascular diseases. It will face huge demand due to the recent trend of minimally invasive procedures. Benefits of these procedures such as fast recovery, reduced hospital stay, and a painless surgical experience will favor the Guidewires Market.

The growing geriatric population and presence of prevalent coronary diseases are factors that can result in increased demand. The guidewires market is projected to grow at a rapid rate from 2016 to 2024 (forecast phase). Reservations by reimbursement companies will hamper the market growth.
Coronary, peripheral, neurovascular, and urology guidewires are the 4 products currently offered in the market. All these products will be of prominent use in the medical sector in the years ahead. In 2013, Terumo Corporation dominated the peripheral guidewires market on account of its expansive product portfolio. Additionally, prominent players of neurovascular guidewires include ASAHI INTECC and Codman Neurovascular.

Browse Details of Report @ https://www.hexaresearch.com/research-report/guidewires-industry

Regions include North America, Latin America, Asia Pacific, Europe, and Middle East & Africa (MEA). North America will lead the guidewires market over the next eight years. This can be attributed to the advanced health infrastructure and cardiovascular and neurovascular diseases in the region. Presence of large manufacturers and their respective specialty products will also favor the regional market growth. Asia Pacific will be the fastest growing market, owing its growth to the economies of China and India.

Research and development play a key role pertaining to the growth of the global market. The companies involved have tried to create cost-effective products to prevent any product recalls. Tip shape retention and flexibility are the prime requirements of health practitioners while handling guidewires. Well-known players in the market are ASAHI INTECC, Terumo Corporation, Boston Scientific Corporation, and Abbott Laboratories.

New product launches and collaborations with healthcare practitioners are a common strategy followed by these players. For instance, Boston Scientific has launched Safari preshaped TAVI guidewires, Fathom Steerable Guidewires, choice Floppy guidewires, Journey Guidewire, and Kinetix Guidewires. The Fathom series has advanced micro fabrication technology which can be used to treat tortuous vasculature. Safari series can retain its shape and comes in three sizes.


Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website - http://www.hexaresearch.com/

Hernia Repair Device Market Size and Analysis Report 2024

The global Hernia Repair Market is expected to reach USD 6.60 billion by 2024. Rigorous research & development activities, growing number of obese patients and high susceptibility of geriatric patients to suffer from hernia are expected to drive the market over the forecast period. Increasing technological sophistication in repair devices and rigorous research and development of the drug-eluting mesh is projected to boost the demand for hernia repair devices and consumables.

Post-operative pain is growing concern post-repair with synthetic mesh. Though the cause of pain varies from patient to patient, a primary reason for pain is inflammation associated with the synthetic mesh. Other chronic illnesses related to the use of implanted mesh are abdominal pain, infection (sepsis), bowel obstruction and adhesion. In spite of increasing technological sophistication in mesh technology, synthetic materials remain the most widely used mesh products for hernia repair especially the polypropylene mesh due to their low cost and easy availability.

The biological mesh is gaining momentum in developed countries especially in the U.S. Biologic mesh development has overcome the problem associated the synthetic mesh including foreign body interaction, chronic inflammation, infection, and stiffness. Presence of favorable reimbursement policies coupled with the well-regulated healthcare insurance and increasing prevalence of an inguinal and ventral hernia in developed economies have rendered increased acceptance of this product.

Browse Details of Report @ https://www.hexaresearch.com/research-report/hernia-repair-market

The above mentioned factors collectively boost demand for overall hernia repair consumables and surgical devices market over the forecast period. Owing to shortcomings of synthetic mesh, manufacturers are working on developing cost-effective and technological advanced mesh. For instance, Ariste Medical is developing drug-eluting mesh. These repair products are anticipated to improve the patient outcomes specifically in vascular procedures including hernia and peripheral bypass hemodialysis processes.

Also, manufacturers are focusing on developing composite or hybrid mesh. The hybrid mesh is a result of the combination of best features of biologic and synthetic mesh. Mesh that combines a minute quantity of synthetic material such as polypropylene and biologic building blocks derived from animal tissue has the property to diminish the hazards of inflammatory reactions along with providing long-term durability. Medtronic and COOK Medical are investing in the development of cost-effective composite mesh. This product may overcome the disadvantages associated with the synthetic mesh such as inflammation, sepsis and abdominal adhesion. These factors render cost advantage over the biologic mesh, which in turn is expected to boost the hernia repair market.

Hexa Research has segmented the global hernia repair market based on product, procedure, and region:
Segmentation by product, 2014 - 2024 (USD Million)
• Consumables
    • Synthetic Mesh
    • Biologic Mesh
• Surgical Devices
Segmentation by procedure, 2014 - 2024 (USD Million)
• Tension Free
• Open Hernia Repair
• Laparoscopic
Segmentation by region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
• Central & South America
    • Brazil
• Middle East & Africa
    • UAE
Key players analyzed:
• Ethicon, Inc.
• Medtronic
• C. R. Bard
• Atrium


Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices-industry

Teeth Whitening Products Market Size and Future Outlook 2024

The global Teeth Whitening Products Market is expected to reach USD 7.40 billion by 2024. The industry is driven by the mounting consumer demand for clean and white teeth coupled with awareness about oral hygiene. Moreover, 99.2% of the people believe that smile is an important social benefit and growing consumer preference for over the counter products in countries such as Germany, France, UK, India and China are anticipated to drive the growth of the market over the forecast period.

The leading teeth whitening products manufacturing companies are focusing on R&D to enhance its product portfolio and are expanding their presence in the global market by acquiring local players of that region. For instance, in April 2017, Colgate-Palmolive acquired Ciba-Geigy, an India-based teeth whitening brand, to expand its reach towards the rural parts of India. These factors are expected to provide an impetus to the growth of the market over the next coming years.

Browse Details of Report @ https://www.hexaresearch.com/research-report/teeth-whitening-products-market

Whitening toothpaste segment holds the largest share in the market in terms of revenue and is expected to maintain its position over the forecast period. Whitening toothpaste has a major role in oral hygiene maintenance. Unhealthy lifestyle accompanied by consumption of liquor, cola, tobacco and other related products which cause discoloration of the teeth are anticipated to drive the market globally.

The whitening strips segment was valued at USD 899.8 million in 2016 and are likely to witness a significant growth as a result of rising consumer demand and the requirement for quick result formulas. Furthermore, initiatives and campaigns have taken up by leading companies such as Colgate-Palmolive, P&G and GlaxoSmithKline to create awareness among consumers to use herbal products for teeth whitening are expected to augment the growth of the market.

The increase of these market is determined mainly by consumer demand which is to be favoured by the rising living standards such as modernization, personality traits and appearance. There is a huge competition in the teeth whitening products market as the market is consolidated. The leading players are acquiring the major local players and expanding its production capacity and presence globally. The leading manufacturers in these markets are Colgate-Palmolive, Proctor & Gamble, GlaxoSmithKline, Johnson & Johnson, Unilever and Henkel.

Hexa Research has segmented the global teeth whitening products market based on type and region:

Segmentation by type, 2014 - 2024 (USD Million)

• Whitening Toothpaste

• Whitening Stripes & gels

• Others

Segmentation by region, 2014 - 2024 (USD Million)

• North America

    • U.S.

• Europe

    • Germany

    • UK

• Asia Pacific

    • China

    • India

• Central & South America

• Middle East and Africa

Key players analyzed

• Colgate-Palmolive

• GlaxoSmithKline

• Johnson & Johnson

• Proctor & Gamble

• Unilever

• Church & Dwight

• Brodie & Stone

• CCA Industries

• GO SMILE

• Henkel

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

U.S. Medical Cannabis Market Share, Size, Analysis and Growth Prospects 2024

The U.S. Medical Cannabis Market is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-medical-cannabis-market 

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer’s disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn’s disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

Hexa Research has segmented the U.S. medical cannabis market based on usage, consumption and state:

Segmentation by usage, 2014 - 2024 (USD Million)

• Chronic Pain

• Arthritis

• Migraine

• Cancer

• Others

Segmentation by consumption, 2014 - 2024 (USD Million)

• Solid Edibles

• Inhalation

• Liquid Edibles

• Topical

Segmentation by state, 2014 - 2024 (USD Million)

• California

• Colorado

• Washington

• Arizona

• Michigan

  

Key players analyzed

• American Cannabis

• Canopy Growth Corporation

• Greengro Technologies

• Medical Marijuana Inc.

• United Cannabis

• Terra Tech Corp.

• Mentor Capital, Inc

• Cannabis Sativa, Inc.

• GBSciences, Inc.

• The Green Solution

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Growth and Trends 2020

The worldwide Idiopathic Thrombocytopenic Purpura Therapeutics Market is projected to attain nearly USD 566 million by 2020. It can expand at a 5.9 % CAGR over the forecast period (2014-2020). The market stood at around USD 382 million in 2013. It is driven by favorable government policies such as the U.S. Orphan Drug Act. Demand of combination therapies like dexamethasone and TPO-RA is another factor which may influence market growth.

ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike. ITP affects nearly 0.3% out of every 100,000 in the U.S. Commercialization of new drugs like IVIG3I 10% and Avatrombopag is anticipated to propel demand over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/idiopathic-thrombocytopenic-purpura-itp-therapeutics-industry

The global Idiopathic Thrombocytopenic Purpura Therapeutics Market is segmented according to products and regions. As per products, the classifications are TPO-RA (thrombopoetin receptor agonist), anti-D immunoglobulin, intravenous immunoglobulin (IVIG), anti-D immunoglobulins, corticosteroids, and others. Corticosteroids were valued over USD 125 million in 2013 and are the most widely preferred drug for treating ITP. Its high share in overall revenues can be attributed to its low price. TPO-RA can experience surging demand on account of commercialization of Avatrombopag.  This can be attributed to the use of TPO-RA in splenectomized patients suffering relapses. Avatrombopag can act as a second line of defense due to its positive clinical trial results.
High response rates displayed by patients administered with Eltrombopag and Romiplostim can positively impact the TPO-RA segment till 2020. Other therapeutic classes are interferon, immunosuppressant, and monoclonal antibodies (mAbs). mAbs such as Rituximab were used frequently in Europe till 2013. However, patent expiry of the same has created scope for drug manufacturers to develop biosimilars.

North America, Europe, Asia Pacific, and RoW (Rest of the World) are regional segments of the worldwide ITP market. North America led the overall industry in 2013 owing to favorable government initiatives, rising ITP cases, and high research funding. Clinical trials based on combination therapy and drug developments are expected to spur regional demand over the forecast period. North America had a revenue share exceeding 40% in 2013.

Europe was the second largest market in 2013 propelled by high product penetration and favorable initiatives pertaining to its production. Asia Pacific is expected to prosper considerably over the next 6 years due to the untapped markets in India and China. Furthermore, sophisticated healthcare and government initiatives in Australia and Japan can contribute significantly to regional demand. 

Notable players of the Idiopathic Thrombocytopenic Purpura Therapeutics Market are Grifols Biologicals Inc.; GlaxoSmithKline (GSK) Plc; Amgen Inc.; and F. Hoffman-La Roche AG. These companies invest robustly in research and development to launch newer products in order to sustain their respective market shares.

GSK recently got approval for its trademark product “Revolade™” by Health Canada, the department of the government of Canada that looks into national public health. This product is a capsule which needs to be taken orally to treat ITP. It can help boost production of blood platelets. Amgen Inc.’s “Nplate” helps restore blood platelets in children. It can act as a viable alternative to treat severe bleeding concurrent with ITP. This drug had generated nearly USD 400 million in 2013. Although Promacta and Nplate received approvals at the same time, the former is expected to dominate the market in the near future.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry